NL-OMON26342招募中不适用
Pharmacokinetics and –dynamics of Dabigatran Etexilate and Rivaroxaban in patients requiring PArenteral Nutrition (the PDER PAN study)
Academic Medical Center, Amsterdam, The Netherlands0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criteria are:
- •-clinically stable adult male and female patients (age between 18 and 75 years),
排除标准
- •Exclusion criteria are:
- •-moderate/severe renal impairment (CKD EPI Creatinine Clearance < 50 mL/min according to http://www.nephron.com/MDRD_GFR.cgi), or moderate/severe hepatic impairment (class B (7-9 points) or class C (10-15 points) at the Child-Pugh score),
研究者
相似试验
已完成
不适用
Pharmacokinetics and *dynamics of Dabigatran Etexilate and Rivaroxaban in patients requiring PArenteral Nutrition (the PDER PAN study)anticoagulantblood thinner10014523NL-OMON38688Academisch Medisch Centrum6
已完成
1 期
Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male SubjectsHealthyNCT02171468Boehringer Ingelheim48
进行中（未招募）
1 期
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve significant levels and thrombin inhibiting activity in the eye?Ocular accessibility of dabigatran in patients with retinal detachmentEUCTR2014-000388-41-NLThe Rotterdam Eye Hospital28
已完成
不适用
Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal fluid?10015917proliferative vitreoretinopathyNL-OMON40980Oogziekenhuis Rotterdam24
已完成
3 期
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)ThromboembolismNCT00680186Boehringer Ingelheim2,589